Thermo Fisher Scientific (NYSE:TMO) Upgraded at Wolfe Research

Thermo Fisher Scientific (NYSE:TMO) was upgraded by investment analysts at Wolfe Research to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other research analysts also recently weighed in on TMO. DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 target price for the company. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Morgan Stanley restated an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Finally, Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus price target of $612.24.

Thermo Fisher Scientific Stock Down 2.7%

Thermo Fisher Scientific stock opened at $480.62 on Monday. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $643.99. The firm has a 50 day moving average price of $480.40 and a 200-day moving average price of $533.68. The company has a market capitalization of $178.61 billion, a P/E ratio of 26.42, a P/E/G ratio of 2.19 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the firm earned $5.15 EPS. The company’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts predict that Thermo Fisher Scientific will post 24.86 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors have recently added to or reduced their stakes in TMO. Legacy Wealth Managment LLC ID boosted its position in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares during the period. High Note Wealth LLC increased its position in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares during the period. Swiss RE Ltd. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $28,000. JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter valued at about $28,000. Finally, Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.